Form 4: Cullinan Therapeutics Executive Acquires Shares and Options

Corrine Savill, Chief Business Officer of Cullinan Therapeutics, reports acquisition of common stock and stock options.

Summary

• Corrine Savill, Chief Business Officer of Cullinan Therapeutics, filed a Form 4.
• The filing reports the acquisition of 37,500 shares of common stock and 75,000 stock options on February 19, 2025.
• The common stock was acquired at a price of $0.
• The exercise price of the stock options is $9.43.
• Following the reported transactions, Savill beneficially owns 240,990 shares of common stock and 75,000 stock options.
• The shares underlying the restricted stock unit vest on an annual basis over four years.
• The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition itself could be seen as slightly positive, but it's not a major event.

Positives

• The acquisition of shares and options by a key executive could be interpreted as a positive signal regarding their confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The acquisition of shares by a key executive may positively influence shareholder sentiment.

Key Dates

Keywords

Form 4, Cullinan Therapeutics, CGEM, Insider Trading, Stock Options, Common Stock, Beneficial Ownership, Corrine Savill, Chief Business Officer